What is Biofrontera?
Biofrontera, headquartered in Leverkusen, Germany, is a specialized biopharmaceutical company focused on the development and commercialization of dermatological drugs and medical cosmetics. Founded in 1997, the company has dedicated itself to creating and marketing innovative solutions for skin care, protection, and treatment. Its product portfolio aims to address unmet needs within the dermatology market, positioning Biofrontera as a key player in advancing skin health through scientific innovation and strategic market penetration.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $47.9M across 2 funding rounds:
Share Placement
$29.9M
Stock Offering
$18M
Share Placement (2021): $29.9M, investors not publicly disclosed
Stock Issuance/Offering (2021): $18M, investors not publicly disclosed
What's next for Biofrontera?
The recent major strategic investment signals a pivotal phase for Biofrontera, likely enabling accelerated development of its product pipeline, expansion into new markets, and enhancement of its sales and marketing infrastructure. This infusion of capital, part of its $47.9M in total financing, suggests a strategic push towards scaling operations and solidifying its competitive advantage in the global dermatology landscape. Future endeavors may include further clinical trials, regulatory approvals, and strategic partnerships to broaden its therapeutic reach and commercial success.
See full Biofrontera company page
